Jones Financial Companies Lllp boosted its holdings in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX – Free Report) by ...

It's often challenging to decide which stocks to invest in. However, some companies look too attractive to pass up. We asked ...

What's considered excellent revenue growth depends on the industry. With that context in mind, consider that Eli Lilly's ...

This writer digs into the CRISPR gene-editing space, asking whether one particular penny stock is worth taking a punt on in his ISA.

Vertex Pharmaceuticals (NasdaqGS:VRTX) announced that its cystic fibrosis treatment, ALYFTREK®, had received regulatory approval from the UK's MHRA, a significant milestone in expanding its market ...

Vertex's Journavx, a new non-opioid pain drug, lands Tier 3 on Optum Rx formularies. Vertex reports $2.91 billion Q4 sales.

The agency approved it based on two Phase III studies showing the drug to be as effective as another combination therapy at improving lung function.

The UK’s Medicines and Healthcare products Regulatory Agency (MHRA) has today approved Alyftrek (triple combination medicine ...

Vertex announced that the United Kingdom Medicines and Healthcare products Regulatory Agency has granted approval for ALYFTREK, a once-daily ...

Vertex Pharmaceuticals operates in a profitable subsector and is poised for further success ...

Rouse had presented with symptoms including intense swelling in her legs that she originally thought could be linked to her ...